Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deven Parmar

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Eclinicalmedicine|July 26, 2021
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in IndiaTaufik Momin, Kevinkumar Kansagra, Hardik Patel, et al.
American Journal of Nephrology|April 24, 2022
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)Dhananjai Agrawal, Deepak Varade, Hardik Shah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2020
A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)Kevinkumar Kansagra, Deven Parmar, Sanjeev Kumar Mendiratta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2020
Reply to Agrawal and KumarKevinkumar Kansagra, Deven Parmar, Sanjeev Kumar Mendiratta, et al.
Clinical Pharmacokinetics|May 17, 2017
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy VolunteersKevinkumar A Kansagra, Deven Parmar, Rajendra H Jani, et al.
The Lancet. Infectious Diseases|March 5, 2022
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection studyBridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, et al.
Metabolism Open|April 9, 2026
Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trialPrabhat Kumar Sharma, Sagar Vivek Redkar, Abhishek Madhav Karmalkar, et al.
Metabolism Open|June 22, 2026
Corrigendum to "Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial" [Metabol Open 30 (2026) 100460]Prabhat Kumar Sharma, Sagar Vivek Redkar, Abhishek Madhav Karmalkar, et al.
Metabolism Open|June 8, 2026
Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitusPrabhat Kumar Sharma, V Viswaprasad, Animesh Choudhary, et al.
Ophthalmology and Therapy|January 23, 2026
A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea<sup>®</sup> in Patients with Wet Age-Related Macular DegenerationMudit Bansal, Punit Singh, Ruchi K Mehta, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Eclinicalmedicine|July 26, 2021
Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in IndiaTaufik Momin, Kevinkumar Kansagra, Hardik Patel, et al.
American Journal of Nephrology|April 24, 2022
Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND)Dhananjai Agrawal, Deepak Varade, Hardik Shah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 20, 2020
A Phase 3, Randomized, Open-label, Noninferiority Trial Evaluating Anti-Rabies Monoclonal Antibody Cocktail (TwinrabTM) Against Human Rabies Immunoglobulin (HRIG)Kevinkumar Kansagra, Deven Parmar, Sanjeev Kumar Mendiratta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 4, 2020
Reply to Agrawal and KumarKevinkumar Kansagra, Deven Parmar, Sanjeev Kumar Mendiratta, et al.
Clinical Pharmacokinetics|May 17, 2017
Phase I Clinical Study of ZYAN1, A Novel Prolyl-Hydroxylase (PHD) Inhibitor to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Oral Administration in Healthy VolunteersKevinkumar A Kansagra, Deven Parmar, Rajendra H Jani, et al.
The Lancet. Infectious Diseases|March 5, 2022
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection studyBridget E Barber, Melissa Fernandez, Hardik Babubhai Patel, et al.
Metabolism Open|April 9, 2026
Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in indian adults with obesity: A phase III randomized non-inferiority trialPrabhat Kumar Sharma, Sagar Vivek Redkar, Abhishek Madhav Karmalkar, et al.
Metabolism Open|June 22, 2026
Corrigendum to "Efficacy and safety of semaglutide injection in comparison with reference semaglutide for chronic weight management in Indian adults with obesity: A phase III randomized non-inferiority trial" [Metabol Open 30 (2026) 100460]Prabhat Kumar Sharma, Sagar Vivek Redkar, Abhishek Madhav Karmalkar, et al.
Metabolism Open|June 8, 2026
Efficacy and safety of novel formulation of semaglutide injection: A multicentre, randomized, comparative, active controlled, phase 3 study in comparison with reference biologic in Indian patients with type 2 diabetes mellitusPrabhat Kumar Sharma, V Viswaprasad, Animesh Choudhary, et al.
Ophthalmology and Therapy|January 23, 2026
A Phase III Randomized Trial Comparing Efficacy, Safety, and Immunogenicity of ZRC-3285 vs. Eylea<sup>®</sup> in Patients with Wet Age-Related Macular DegenerationMudit Bansal, Punit Singh, Ruchi K Mehta, et al.
Pageof 4